Open Nav

Handa Pharmaceuticals, Inc.

  • Stephen Cary, Handa Pharmaceuticals, Inc.

Introduce Handa Pharmaceuticals as an Innovative Specialty Drug Delivery Company

  • Date:Wednesday, October 17
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Working with medical experts, Handa identifies unmet medical needs that can be addressed by improving marketed medicines using innovative drug delivery technologies. Handa will create significant value by developing, owning and monetizing innovative intellectual property, and commercializing its products globally.
  • Company Website:www.handapharma.com.tw/en/index.php
  • Company HQ City:Tainan City
  • Company HQ Country:Taiwan
  • Market Cap:US$103 million as of 19-Jul-18
  • Ticker:6620:TT
  • Exchange:Taiwan Exchange
  • CEO/Top Company Official:Fang-Yu "Bill" Liu
  • Year Founded:2014
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :HND-020
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Additional Information/Comments:ONCORE™ – Making Oncology Drugs Better ONCORE™ is Handa’s proprietary drug delivery technology that was developed to improve the safety and patient compliance profiles of the Tyrosine Kinase Inhibitor (TKI) class of oncology drugs. ONCORE™ employs a unique salt formulation that is capable of minimizing the pH effect of the drug in the gastrointestinal tract, which enables: * Elimination of the drug’s food effect * Elimination of the acid reducing agent/Proton Pump Inhibitor (PPI) co-administration restrictions, to provide better care for TKI-treated patients with prevalently comorbid GI conditions ONCORE™ can also be used to improve a TKI’s systemic absorption, resulting in: * Dose reduction * Reduced exposure of the drug in the gastrointestinal (GI) tract * Potential for extended release, once daily dosing to further increase successful outcomes by improving patient compliance
Speakers
Stephen Cary
Handa Pharmaceuticals, Inc.
Back